Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICHOL TRIAL: niraparib plus abemaciclib in late-line ovarian cancer
2022-501910-79-01Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and abemaciclib in ovarian cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Planned start May 2024; status: authorised.
02
Drugs
niraparibabemaciclib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2022-501910-79-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501910-79-01.